Latest Cancer treatments Stories
- Results from two large trials individually showed an improvement in the secondary endpoint of overall survival for patients with the most common EGFR mutation (Del19) RIDGEFIELD, Conn., Jan.
Company continues to expand its clinical collaborations with National Comprehensive Cancer Network centers across a broad range of clinically actionable mutations in major cancer types
Lead Immunotherapy Product Candidate GEN-1 to Enter Dose Escalating Clinical Study in the Second Half of 2015 LAWRENCEVILLE, N.J., Jan.
Active Immunotherapy Targets hTERT Gene Associated with 85% of Cancers PLYMOUTH MEETING, Pa., Dec. 18, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
CYRAMZA is the first treatment approved in the U.S. for use in combination with docetaxel in second-line metastatic non-small cell lung cancer INDIANAPOLIS, Dec.
- A poem in which the author retracts something said in an earlier poem.
More Images (3 images) »